Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.59 |
| ▸ | ITGAV | P06756 | 3/20 | 0.59 |
| ▸ | MC4R | P32245 | 13/20 | 0.51 |
| ▸ | MC5R | P33032 | 13/20 | 0.51 |
| ▸ | MC3R | P41968 | 13/20 | 0.51 |
| ▸ | MC1R | Q01726 | 13/20 | 0.51 |
| ▸ | CTSG | P08311 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.45 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908267 | 0.97 | ITGB3 (0.63) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13014865 | 0.97 | ITGB3 (0.63) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13014695 | 0.96 | ITGB3 (0.60) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL14845482 | 0.95 | ITGB3 (0.52) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13014734 | 0.93 | ITGB3 (0.59) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL14090938 | 0.93 | ITGB3 (0.64) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL12947539 | 0.91 | ITGB3 (0.56) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL9909402 | 0.91 | ITGB3 (0.56) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL15335356 | 0.91 | ITGB3 (0.53) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL14845480 | 0.91 | ITGB3 (0.52) | ITGB3ITGAVMC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | disclosed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GAS6, LNPEP, BMP6 | ITGB3 3073/4885ITGAV 2257/4885MC4R 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.